Pharmacotherapy in body dysmorphic disorder

relapse prevention and novel treatments

Nancy Dong, Vera Nezgovorova, Kevin Hong, Eric Hollander

Research output: Contribution to journalArticle

Abstract

Introduction: Body dysmorphic disorder is a debilitating disorder that often presents with significant delusionality, low insight, and both medical and psychiatric comorbidities, presenting a challenge for treatment and long-term management. Its typically chronic course requires that therapy be continued indefinitely, but only a few studies of long-term pharmacotherapeutic management exist. Areas covered: The authors discuss the current understanding of body dysmorphic disorder, focusing specifically on: epidemiology, clinical presentation, challenges in treatment, treatment options, and the importance of the further study of the long-term management of the disorder. Expert opinion: Serotonin reuptake inhibitors are the established drug of choice in patients with body dysmorphic disorder. Initial studies suggest that other agents such as augmentation antipsychotic medication may also be of use in combination with serotonin reuptake inhibitors, but there is a lack of studies comparing new treatments to serotonin reuptake inhibitors. Due to the chronic nature of body dysmorphic disorder, further research is needed to clarify the role of pharmacotherapy in long-term management and relapse prevention. Future studies should explore the long-term use of therapies and combinations of different therapeutics with the goal of effectively managing this debilitating, chronic condition.

Original languageEnglish (US)
JournalExpert Opinion on Pharmacotherapy
DOIs
StatePublished - Jan 1 2019

Fingerprint

Body Dysmorphic Disorders
Secondary Prevention
Drug Therapy
Serotonin Uptake Inhibitors
Therapeutics
Expert Testimony
Antipsychotic Agents
Psychiatry
Comorbidity
Epidemiology

Keywords

  • antidepressants
  • BDD
  • body dysmorphic disorder
  • obsessive compulsive disorder
  • obsessive compulsive-related disorder
  • OCD
  • OCRD
  • SRI
  • SSRI

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacotherapy in body dysmorphic disorder : relapse prevention and novel treatments. / Dong, Nancy; Nezgovorova, Vera; Hong, Kevin; Hollander, Eric.

In: Expert Opinion on Pharmacotherapy, 01.01.2019.

Research output: Contribution to journalArticle

@article{a46e580c269b4f7a98650a4c78e4f57e,
title = "Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments",
abstract = "Introduction: Body dysmorphic disorder is a debilitating disorder that often presents with significant delusionality, low insight, and both medical and psychiatric comorbidities, presenting a challenge for treatment and long-term management. Its typically chronic course requires that therapy be continued indefinitely, but only a few studies of long-term pharmacotherapeutic management exist. Areas covered: The authors discuss the current understanding of body dysmorphic disorder, focusing specifically on: epidemiology, clinical presentation, challenges in treatment, treatment options, and the importance of the further study of the long-term management of the disorder. Expert opinion: Serotonin reuptake inhibitors are the established drug of choice in patients with body dysmorphic disorder. Initial studies suggest that other agents such as augmentation antipsychotic medication may also be of use in combination with serotonin reuptake inhibitors, but there is a lack of studies comparing new treatments to serotonin reuptake inhibitors. Due to the chronic nature of body dysmorphic disorder, further research is needed to clarify the role of pharmacotherapy in long-term management and relapse prevention. Future studies should explore the long-term use of therapies and combinations of different therapeutics with the goal of effectively managing this debilitating, chronic condition.",
keywords = "antidepressants, BDD, body dysmorphic disorder, obsessive compulsive disorder, obsessive compulsive-related disorder, OCD, OCRD, SRI, SSRI",
author = "Nancy Dong and Vera Nezgovorova and Kevin Hong and Eric Hollander",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/14656566.2019.1610385",
language = "English (US)",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Pharmacotherapy in body dysmorphic disorder

T2 - relapse prevention and novel treatments

AU - Dong, Nancy

AU - Nezgovorova, Vera

AU - Hong, Kevin

AU - Hollander, Eric

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Body dysmorphic disorder is a debilitating disorder that often presents with significant delusionality, low insight, and both medical and psychiatric comorbidities, presenting a challenge for treatment and long-term management. Its typically chronic course requires that therapy be continued indefinitely, but only a few studies of long-term pharmacotherapeutic management exist. Areas covered: The authors discuss the current understanding of body dysmorphic disorder, focusing specifically on: epidemiology, clinical presentation, challenges in treatment, treatment options, and the importance of the further study of the long-term management of the disorder. Expert opinion: Serotonin reuptake inhibitors are the established drug of choice in patients with body dysmorphic disorder. Initial studies suggest that other agents such as augmentation antipsychotic medication may also be of use in combination with serotonin reuptake inhibitors, but there is a lack of studies comparing new treatments to serotonin reuptake inhibitors. Due to the chronic nature of body dysmorphic disorder, further research is needed to clarify the role of pharmacotherapy in long-term management and relapse prevention. Future studies should explore the long-term use of therapies and combinations of different therapeutics with the goal of effectively managing this debilitating, chronic condition.

AB - Introduction: Body dysmorphic disorder is a debilitating disorder that often presents with significant delusionality, low insight, and both medical and psychiatric comorbidities, presenting a challenge for treatment and long-term management. Its typically chronic course requires that therapy be continued indefinitely, but only a few studies of long-term pharmacotherapeutic management exist. Areas covered: The authors discuss the current understanding of body dysmorphic disorder, focusing specifically on: epidemiology, clinical presentation, challenges in treatment, treatment options, and the importance of the further study of the long-term management of the disorder. Expert opinion: Serotonin reuptake inhibitors are the established drug of choice in patients with body dysmorphic disorder. Initial studies suggest that other agents such as augmentation antipsychotic medication may also be of use in combination with serotonin reuptake inhibitors, but there is a lack of studies comparing new treatments to serotonin reuptake inhibitors. Due to the chronic nature of body dysmorphic disorder, further research is needed to clarify the role of pharmacotherapy in long-term management and relapse prevention. Future studies should explore the long-term use of therapies and combinations of different therapeutics with the goal of effectively managing this debilitating, chronic condition.

KW - antidepressants

KW - BDD

KW - body dysmorphic disorder

KW - obsessive compulsive disorder

KW - obsessive compulsive-related disorder

KW - OCD

KW - OCRD

KW - SRI

KW - SSRI

UR - http://www.scopus.com/inward/record.url?scp=85065174746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065174746&partnerID=8YFLogxK

U2 - 10.1080/14656566.2019.1610385

DO - 10.1080/14656566.2019.1610385

M3 - Article

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

ER -